Wall Street analysts claim Microsoft's $13 billion OpenAI investment is "some of the best money ever spent" despite bankruptcy reports — Here's why
Microsoft's strategic partnership with OpenAI leaves it with the longer end of the stick, according to market analysts.
Neurocrine (NBIX) Gets a Buy from Oppenheimer
Oppenheimer analyst Jay Olson maintained a Buy rating on Neurocrine (NBIX – Research Report) today and set a price target of $192.00. The ...
Neurocrine (NBIX) Receives a Buy from Jefferies
Jefferies analyst Akash Tewari maintained a Buy rating on Neurocrine (NBIX – Research Report) today and set a price target of $158.00.